SCHEDULE: Decheng Capital Discloses 5% Stake in Upstream Bio

Decheng Capital Global Life Sciences Fund IV, L.P. has reported a 5% beneficial ownership stake in Upstream Bio, Inc. common stock.

Summary

• Decheng Capital Global Life Sciences Fund IV, L.P. holds 2,724,868 shares of Upstream Bio, Inc. common stock.
• This holding represents 5.0% of the total outstanding common stock of the issuer.
• The reporting persons include Decheng Capital Management IV (Cayman), LLC, and Xiangmin Cui, who share voting and investment authority.
• The ownership percentage is based on 54,419,986 shares outstanding as of March 20, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure regarding ownership status, which does not inherently signal a change in company performance or strategy.

Positives

• Institutional investor maintains a significant 5% stake, signaling long-term interest in the company's equity.

Negatives

• None identified in this ownership disclosure.

Risks

• Concentration of voting power among a small group of related entities.
• Market volatility associated with biotech sector investments.

Future Outlook

No specific forward-looking guidance provided; this is a standard beneficial ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory requirements for institutional investors reaching the 5% ownership threshold, reflecting typical capital allocation strategies within the biotechnology sector.

Comparison to Industry Standards

• The filing adheres to standard SEC reporting requirements for beneficial ownership under Section 13(d) of the Securities Exchange Act.
• The 5% threshold is a standard benchmark for institutional disclosure in the U.S. equity markets.

Stakeholder Impact

• Shareholders may view the maintenance of a 5% stake by an institutional investor as a sign of stability.

Next Steps

• Reporting persons will continue to monitor their investment in Upstream Bio, Inc.

Key Dates

Keywords

Upstream Bio, Schedule 13G, Beneficial Ownership, Decheng Capital, Biotech, Equity Stake